The present invention provides a composition comprising Herpes Simplex Virus (HSV) particles in a defined liquid stabilization buffer, which may further comprise a pharmaceutically acceptable carrier and/or an adjuvant; a pharmaceutically acceptable dosage form and use of the compositions for therapy are also provided.